Retinopathy of prematurity

Retinopathy of prematurity (ROP) is a devastating neurovascular disease of the retina in newborn infants that can lead to vision deficits or even blindness. In this concise review we discuss our current knowledge about diagnosis, etiology, pathogenesis, intervention, and outcomes of the disease. Maj...

Full description

Saved in:

Bibliographic Details
Published in:	Developmental medicine and child neurology Vol. 65; no. 5; pp. 625 - 631
Main Authors:	Dammann, Olaf, Hartnett, M. Elizabeth, Stahl, Andreas
Format:	Journal Article
Language:	English
Published:	England 01.05.2023
Subjects:	Endothelial Growth Factors Humans Infant Infant, Newborn Infant, Premature Retina Retinopathy of Prematurity - diagnosis Retinopathy of Prematurity - etiology Retinopathy of Prematurity - therapy Vascular Endothelial Growth Factor A
ISSN:	0012-1622, 1469-8749, 1469-8749
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Retinopathy of prematurity (ROP) is a devastating neurovascular disease of the retina in newborn infants that can lead to vision deficits or even blindness. In this concise review we discuss our current knowledge about diagnosis, etiology, pathogenesis, intervention, and outcomes of the disease. Major advancements have been made both in categorizing the disease in the new International Classification of Retinopathy of Prematurity, Third Edition classification and in treating severe ROP with anti‐vascular endothelial growth factor (VEGF) agents. New development always creates new questions and opens up new areas of research. We will discuss in this review both the benefits and downsides of the new anti‐VEGF treatment approaches in ROP, especially in light of our improved understanding of the underlying ROP pathophysiology. We also offer pointers to areas where more research is needed. What this paper adds Concise update on all aspects of retinopathy of prematurity (ROP), including advances in understanding and treatment. Benefits and risks of the new treatment method of anti‐vascular endothelial growth factor injections in ROP are discussed. New research areas that deserve attention in the coming years are identified. What this paper adds Concise update on all aspects of retinopathy of prematurity (ROP), including advances in understanding and treatment. Benefits and risks of the new treatment method of anti‐vascular endothelial growth factor injections in ROP are discussed. New research areas that deserve attention in the coming years are identified. This article provides a concise up‐to‐date overview of retinopathy of prematurity and its etiology, pathogenesis, diagnosis, treatment, and outcomes.
AbstractList	Retinopathy of prematurity (ROP) is a devastating neurovascular disease of the retina in newborn infants that can lead to vision deficits or even blindness. In this concise review we discuss our current knowledge about diagnosis, etiology, pathogenesis, intervention, and outcomes of the disease. Major advancements have been made both in categorizing the disease in the new International Classification of Retinopathy of Prematurity, Third Edition classification and in treating severe ROP with anti-vascular endothelial growth factor (VEGF) agents. New development always creates new questions and opens up new areas of research. We will discuss in this review both the benefits and downsides of the new anti-VEGF treatment approaches in ROP, especially in light of our improved understanding of the underlying ROP pathophysiology. We also offer pointers to areas where more research is needed. WHAT THIS PAPER ADDS: Concise update on all aspects of retinopathy of prematurity (ROP), including advances in understanding and treatment. Benefits and risks of the new treatment method of anti-vascular endothelial growth factor injections in ROP are discussed. New research areas that deserve attention in the coming years are identified.Retinopathy of prematurity (ROP) is a devastating neurovascular disease of the retina in newborn infants that can lead to vision deficits or even blindness. In this concise review we discuss our current knowledge about diagnosis, etiology, pathogenesis, intervention, and outcomes of the disease. Major advancements have been made both in categorizing the disease in the new International Classification of Retinopathy of Prematurity, Third Edition classification and in treating severe ROP with anti-vascular endothelial growth factor (VEGF) agents. New development always creates new questions and opens up new areas of research. We will discuss in this review both the benefits and downsides of the new anti-VEGF treatment approaches in ROP, especially in light of our improved understanding of the underlying ROP pathophysiology. We also offer pointers to areas where more research is needed. WHAT THIS PAPER ADDS: Concise update on all aspects of retinopathy of prematurity (ROP), including advances in understanding and treatment. Benefits and risks of the new treatment method of anti-vascular endothelial growth factor injections in ROP are discussed. New research areas that deserve attention in the coming years are identified. Retinopathy of prematurity (ROP) is a devastating neurovascular disease of the retina in newborn infants that can lead to vision deficits or even blindness. In this concise review we discuss our current knowledge about diagnosis, etiology, pathogenesis, intervention, and outcomes of the disease. Major advancements have been made both in categorizing the disease in the new International Classification of Retinopathy of Prematurity, Third Edition classification and in treating severe ROP with anti‐vascular endothelial growth factor (VEGF) agents. New development always creates new questions and opens up new areas of research. We will discuss in this review both the benefits and downsides of the new anti‐VEGF treatment approaches in ROP, especially in light of our improved understanding of the underlying ROP pathophysiology. We also offer pointers to areas where more research is needed. What this paper adds Concise update on all aspects of retinopathy of prematurity (ROP), including advances in understanding and treatment. Benefits and risks of the new treatment method of anti‐vascular endothelial growth factor injections in ROP are discussed. New research areas that deserve attention in the coming years are identified. What this paper adds Concise update on all aspects of retinopathy of prematurity (ROP), including advances in understanding and treatment. Benefits and risks of the new treatment method of anti‐vascular endothelial growth factor injections in ROP are discussed. New research areas that deserve attention in the coming years are identified. This article provides a concise up‐to‐date overview of retinopathy of prematurity and its etiology, pathogenesis, diagnosis, treatment, and outcomes. Retinopathy of prematurity (ROP) is a devastating neurovascular disease of the retina in newborn infants that can lead to vision deficits or even blindness. In this concise review we discuss our current knowledge about diagnosis, etiology, pathogenesis, intervention, and outcomes of the disease. Major advancements have been made both in categorizing the disease in the new International Classification of Retinopathy of Prematurity, Third Edition classification and in treating severe ROP with anti-vascular endothelial growth factor (VEGF) agents. New development always creates new questions and opens up new areas of research. We will discuss in this review both the benefits and downsides of the new anti-VEGF treatment approaches in ROP, especially in light of our improved understanding of the underlying ROP pathophysiology. We also offer pointers to areas where more research is needed. WHAT THIS PAPER ADDS: Concise update on all aspects of retinopathy of prematurity (ROP), including advances in understanding and treatment. Benefits and risks of the new treatment method of anti-vascular endothelial growth factor injections in ROP are discussed. New research areas that deserve attention in the coming years are identified.
Author	Hartnett, M. Elizabeth Stahl, Andreas Dammann, Olaf
Author_xml	– sequence: 1 givenname: Olaf orcidid: 0000-0002-0046-4863 surname: Dammann fullname: Dammann, Olaf email: olaf.dammann@tufts.edu organization: Norwegian University of Science & Technology – sequence: 2 givenname: M. Elizabeth surname: Hartnett fullname: Hartnett, M. Elizabeth organization: University of Utah Health – sequence: 3 givenname: Andreas orcidid: 0000-0002-8013-7597 surname: Stahl fullname: Stahl, Andreas organization: University Medicine Greifswald
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36408783$$D View this record in MEDLINE/PubMed
BookMark	eNp90MtLxDAQBvAgK-5DLx49yB5F6Jo0j6ZH2fUFq4LoOaSzKUb6MkmR_vd27e5FxLnM5fcNzDdFo6quDEKnBC9IP1ebEqoF4UzIAzQhTKSRTFg6QhOMSRwREcdjNPX-A2NMBWdHaEwFwzKRdILOXkywVd3o8N7N63zeOFPq0DobumN0mOvCm5PdnqG325vX5X20fr57WF6vI2CUyAhAJIwJRhmJITF5xqkGDkZQITODKU15BgBpljGdZkkKgguiDeFxwiUITGfoYrjbuPqzNT6o0nowRaErU7dexQmVLKWSkJ6e72iblWajGmdL7Tq1_6cHeADgau-dyRXYoIOtq-C0LRTBaluZ2lamfirrI5e_Ivurf2Iy4C9bmO4fqVaPy6ch8w3eSnn_
CitedBy_id	crossref_primary_10_2147_OPTH_S519292 crossref_primary_10_3928_23258160_20250604_02 crossref_primary_10_1016_j_arcmed_2024_102967 crossref_primary_10_1055_a_2369_6690 crossref_primary_10_1080_02713683_2025_2503202 crossref_primary_10_1146_annurev_vision_093022_021420 crossref_primary_10_1186_s12886_023_03055_4 crossref_primary_10_1007_s00417_025_06801_0 crossref_primary_10_1080_17469899_2023_2200934 crossref_primary_10_1002_mco2_668 crossref_primary_10_1016_j_heliyon_2024_e30840 crossref_primary_10_1542_neo_26_6_023 crossref_primary_10_1038_s41390_024_03479_8 crossref_primary_10_1186_s12886_025_03867_6 crossref_primary_10_1186_s12931_024_03039_y crossref_primary_10_1007_s12519_025_00919_1 crossref_primary_10_1049_qtc2_70008 crossref_primary_10_3389_fped_2025_1629765 crossref_primary_10_3390_ijms242115680 crossref_primary_10_3389_fped_2024_1404196 crossref_primary_10_15690_pf_v22i2_2869 crossref_primary_10_1016_j_preteyeres_2023_101230 crossref_primary_10_3390_pediatric16030050 crossref_primary_10_1016_j_exer_2024_110170 crossref_primary_10_1002_ima_70191 crossref_primary_10_1016_j_exer_2023_109547 crossref_primary_10_3390_ijms252111850 crossref_primary_10_2196_60330 crossref_primary_10_3390_children10030567 crossref_primary_10_1111_cbdd_14504 crossref_primary_10_1016_j_bspc_2025_107521 crossref_primary_10_1038_s41372_025_02368_0 crossref_primary_10_1007_s12098_024_05358_w crossref_primary_10_1016_j_ajo_2025_02_040 crossref_primary_10_3389_fphar_2025_1615910 crossref_primary_10_3390_children12040509 crossref_primary_10_3390_children12030392 crossref_primary_10_1002_14651858_CD016171 crossref_primary_10_1016_j_exer_2024_110145 crossref_primary_10_3390_antiox12020422 crossref_primary_10_1111_aos_15751 crossref_primary_10_3390_nu17091417 crossref_primary_10_1038_s41433_025_03787_1 crossref_primary_10_1007_s10792_025_03410_y crossref_primary_10_1016_j_exer_2023_109518 crossref_primary_10_3390_jpm14040379 crossref_primary_10_1007_s10528_023_10433_6 crossref_primary_10_3390_biomedicines12091937 crossref_primary_10_1111_dmcn_16274 crossref_primary_10_1038_s41390_025_04251_2 crossref_primary_10_1016_j_pedn_2024_06_020 crossref_primary_10_2147_IJN_S532074 crossref_primary_10_3390_jimaging10010008 crossref_primary_10_1080_14767058_2025_2454374 crossref_primary_10_3390_jcm13144034 crossref_primary_10_1038_s41598_024_84030_x
Cites_doi	10.1038/eye.2008.128 10.1111/j.1651-2227.2011.02445.x 10.1001/jamapediatrics.2017.4838 10.1001/jama.2022.10564 10.1038/s41372-019-0357-2 10.1016/S0002-9394(42)92088-9 10.1136/fetalneonatal-2011-301121 10.1167/iovs.17-21931 10.1007/s10456‐018‐9618‐5 10.2147/EB.S94436 10.1016/S0140-6736(13)60178-6 10.1167/tvst.9.2.5 10.1001/archophthalmol.2011.319 10.1038/s41433-021-01543-9 10.1111/apa.15945 10.1001/jamaophthalmol.2014.2772 10.1136/bjophthalmol‐2021‐319254 10.1016/j.ophtha.2018.05.001 10.1007/s00417-018-4162-y 10.1542/peds.2020-039966 10.1007/s10456-007-9066-0 10.1371/journal.pone.0230678 10.1001/jamaophthalmol.2017.2069 10.3928/01913913-20210223-01 10.1016/j.jaapos.2022.03.003 10.1136/bmjopen-2018-025440 10.1016/j.survophthal.2018.04.002 10.1038/s41598-022-15804-4 10.1016/j.ophtha.2020.11.012 10.1016/S2352-4642(21)00195-4 10.1186/1742-2094-11-87 10.1016/S0140-6736(19)31344-3 10.1172/jci.insight.140363 10.1111/aos.14852 10.1136/bjophthalmol-2017-311345 10.1038/s41372‐022‐01489‐0 10.1016/j.ophtha.2022.06.042 10.1182/blood-2006-07-037952 10.1001/jamapediatrics.2016.4396 10.3389/fped.2021.796143 10.1053/j.semperi.2019.05.012 10.1073/pnas.92.23.10457 10.1136/bjophthalmol-2019-314429 10.1097/MD.0000000000017512 10.1542/peds.2015-3218 10.4103/ijo.IJO_1827_19 10.1038/s41598-018-30087-4 10.1016/j.ophtha.2016.12.025 10.3233/NPM-210826 10.1016/j.ophtha.2014.07.050 10.1038/nprot.2009.187 10.1186/s12974-017-0943-1 10.1038/s41390-021-01625-0 10.1167/iovs.18-25525 10.1542/peds.2018-3061 10.1167/iovs.13-12496 10.1016/j.ophtha.2021.05.031 10.1056/NEJMoa1007374 10.1542/peds.2020-016618 10.1016/j.ajpath.2019.11.009 10.1038/pr.2013.205 10.1038/s41598-019-56155-x 10.1542/peds.2018-3537 10.1016/j.clp.2019.05.008
ContentType	Journal Article
Copyright	2022 The Authors. published by John Wiley & Sons Ltd on behalf of Mac Keith Press. 2022 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press.
Copyright_xml	– notice: 2022 The Authors. published by John Wiley & Sons Ltd on behalf of Mac Keith Press. – notice: 2022 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press.
DBID	24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1111/dmcn.15468
DatabaseName	Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1469-8749
EndPage	631
ExternalDocumentID	36408783 10_1111_dmcn_15468 DMCN15468
Genre	reviewArticle Journal Article Review
GroupedDBID	--- --Z .3N .55 .GA .GJ .Y3 0-V 05W 0R~ 10A 1CY 1OB 1OC 24P 29F 2WC 31~ 33P 36B 3O- 3SF 3V. 4.4 41~ 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 7RV 7X7 8-0 8-1 8-3 8-4 8-5 88E 88I 8AF 8AO 8FI 8FJ 8UM 930 A01 A03 AAESR AAEVG AAGKA AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AAQOH AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABGDZ ABITZ ABIVO ABJNI ABOCM ABPPZ ABPVW ABQWH ABUWG ABVKB ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOD ACGOF ACMXC ACNCT ACPOU ACQPF ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFKRA AFKSM AFPWT AFZJQ AHBTC AHEFC AHMBA AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALSLI ALUQN ALVPJ AMBMR AMYDB AN0 ARALO ASPBG ATUGU AVWKF AZBYB AZFZN AZQEC AZVAB BAFTC BAWUL BDRZF BENPR BFHJK BHBCM BKEYQ BMXJE BNQBC BPHCQ BROTX BRXPI BVXVI BY8 C45 CAG CCPQU CHEAL CJNVE COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 DWQXO E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC FYBCS FYUFA G-S G.N GNUQQ GODZA H.X HCIFZ HF~ HGLYW HMCUK HVGLF HZ~ IX1 J0M K48 KBYEO L98 LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M0P M1P M2M M2P M2Q MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NAPCQ NF~ O66 O9- OHT OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PCD PQEDU PQQKQ PROAC PSQYO PSYQQ Q.N Q11 QB0 R.K RCA RIWAO RJQFR ROL RX1 S0X SAMSI SUPJJ TEORI TWZ UB1 UKHRP V9Y VH1 W8V W99 WBKPD WH7 WHG WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 XOL YCJ YQJ YYQ ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX ABUFD AEFGJ AEYWJ AFFHD AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CITATION O8X PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM PKN 7X8
ID	FETCH-LOGICAL-c4318-cc6744643412c7efb53ac5ce6368be03395bccc9bb4a9b79c6561ae152758c603
IEDL.DBID	24P
ISICitedReferencesCount	73
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000888468200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0012-1622 1469-8749
IngestDate	Wed Oct 01 12:51:08 EDT 2025 Wed Feb 19 02:24:42 EST 2025 Sat Nov 29 02:11:22 EST 2025 Tue Nov 18 22:23:49 EST 2025 Wed Jan 22 16:23:04 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
License	Attribution-NonCommercial-NoDerivs 2022 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4318-cc6744643412c7efb53ac5ce6368be03395bccc9bb4a9b79c6561ae152758c603
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ORCID	0000-0002-0046-4863 0000-0002-8013-7597
OpenAccessLink	https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fdmcn.15468
PMID	36408783
PQID	2738493811
PQPubID	23479
PageCount	7
ParticipantIDs	proquest_miscellaneous_2738493811 pubmed_primary_36408783 crossref_citationtrail_10_1111_dmcn_15468 crossref_primary_10_1111_dmcn_15468 wiley_primary_10_1111_dmcn_15468_DMCN15468
PublicationCentury	2000
PublicationDate	May 2023
PublicationDateYYYYMMDD	2023-05-01
PublicationDate_xml	– month: 05 year: 2023 text: May 2023
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Developmental medicine and child neurology
PublicationTitleAlternate	Dev Med Child Neurol
PublicationYear	2023
References	2019; 98 2021; 128 2018; 125 2020; 15 2022; 26 2014; 132 1942; 25 2007; 109 2012; 97 2021; 35 2018; 8 2020; 5 2017; 30 2019; 60 2011; 129 2018; 172 2013; 54 2020; 9 2021; 110 2022; 328 2019; 394 2017; 124 2014; 11 2011; 364 2009; 23 2018; 142 2021; 9 2019; 9 2021; 5 1995; 92 2021; 147 2015; 122 2018; 102 2019; 39 2020; 104 2017; 171 2018; 63 2013; 382 2007; 10 2017; 135 2019; 144 2021; 91 2021; 58 2022; 100 2020; 190 2017; 14 2017; 58 2022 2021 2019; 43 2019; 46 2013; 74 2022; 12 2018 2022; 15 2019; 257 2020; 68 2016; 137 2009; 4 2016; 8 2011; 100 e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_42_1 e_1_2_10_40_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_53_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_55_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_57_1 e_1_2_10_58_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_11_1 e_1_2_10_32_1 e_1_2_10_30_1 e_1_2_10_51_1 Gilbert C (e_1_2_10_66_1) 2017; 30 e_1_2_10_61_1 e_1_2_10_29_1 e_1_2_10_63_1 e_1_2_10_27_1 e_1_2_10_65_1 e_1_2_10_25_1 e_1_2_10_48_1 e_1_2_10_24_1 e_1_2_10_45_1 e_1_2_10_22_1 e_1_2_10_43_1 e_1_2_10_20_1 e_1_2_10_41_1 e_1_2_10_52_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_54_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_38_1 e_1_2_10_56_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_59_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_31_1 e_1_2_10_50_1 e_1_2_10_60_1 e_1_2_10_62_1 e_1_2_10_64_1 e_1_2_10_28_1 e_1_2_10_49_1 e_1_2_10_26_1 e_1_2_10_47_1
References_xml	– volume: 128 start-page: e51 issue: 10 year: 2021 end-page: e68 article-title: International Classification of Retinopathy of Prematurity publication-title: Third Edition. Ophthalmology. – volume: 110 start-page: 2521 issue: 9 year: 2021 end-page: 8 article-title: The prenatal phase of retinopathy of prematurity publication-title: Acta Paediatr. – volume: 15 issue: 3 year: 2020 article-title: Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity publication-title: Plos One. – volume: 98 issue: 42 year: 2019 article-title: Cumulative evidence for association of sepsis and retinopathy of prematurity publication-title: Medicine (Baltimore). – volume: 60 start-page: 1286 issue: 5 year: 2019 end-page: 97 article-title: Discovering Mechanisms in the Changing and Diverse Pathology of Retinopathy of Prematurity: The Weisenfeld Award Lecture publication-title: Investigative Opthalmology & Visual Science. – volume: 12 start-page: 11675 issue: 1 year: 2022 article-title: Early and late onset sepsis and retinopathy of prematurity in a cohort of preterm infants publication-title: Sci Rep. – volume: 171 issue: 3 year: 2017 article-title: Variation in Performance of Neonatal Intensive Care Units in the United States publication-title: JAMA Pediatrics. – volume: 129 start-page: 1555 issue: 12 year: 2011 end-page: 63 article-title: Neonatal Bacteremia and Retinopathy of Prematurity: The ELGAN Study publication-title: Arch Ophthalmol. – volume: 364 start-page: 603 issue: 7 year: 2011 end-page: 15 article-title: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity publication-title: N Engl J Med. – volume: 43 start-page: 381 issue: 6 year: 2019 end-page: 9 article-title: Retinopathy of prematurity, visual and neurodevelopmental outcome, and imaging of the central nervous system publication-title: Semin Perinatol. – volume: 124 start-page: 619 issue: 5 year: 2017 end-page: 33 article-title: Anti‐Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity publication-title: Ophthalmology. – volume: 25 start-page: 203 year: 1942 end-page: 4 article-title: Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens publication-title: Am J Opthalmol. – volume: 97 start-page: F371 issue: 5 year: 2012 end-page: 5 article-title: Aggressive posterior retinopathy of prematurity in large preterm babies in South India publication-title: Arch Dis Child Fetal Neonatal Ed. – volume: 46 start-page: 593 issue: 3 year: 2019 end-page: 9 article-title: Oxygen Saturation and Retinopathy of Prematurity publication-title: Clin Perinatol. – volume: 23 start-page: 2137 issue: 11 year: 2009 end-page: 9 article-title: UK retinopathy of prematurity guideline publication-title: Eye (Lond). – volume: 9 year: 2021 article-title: Vascular Endothelial Growth Factor Signaling in Models of Oxygen‐Induced Retinopathy: Insights Into Mechanisms of Pathology in Retinopathy of Prematurity publication-title: Front Pediatr. – volume: 142 issue: 6 year: 2018 article-title: Screening Examination of Premature Infants for Retinopathy of Prematurity publication-title: Pediatrics. – volume: 135 start-page: 854 issue: 8 year: 2017 end-page: 61 article-title: Reduction of Rod and Cone Function in 6.5‐Year‐Old Children Born Extremely Preterm publication-title: JAMA ophthalmology. – year: 2022 article-title: A Network Meta‐Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept and Laser for Retinopathy of Prematurity publication-title: Ophthalmology. – volume: 102 start-page: 1041 issue: 8 year: 2018 end-page: 6 article-title: Vision in former very low birthweight young adults with and without retinopathy of prematurity compared with term born controls: the NZ 1986 VLBW follow‐up study publication-title: British Journal of Ophthalmology. – volume: 8 start-page: 11875 issue: 1 year: 2018 article-title: Antenatal IL‐1‐dependent inflammation persists postnatally and causes retinal and sub‐retinal vasculopathy in progeny publication-title: Sci Rep. – volume: 137 issue: 4 year: 2016 article-title: Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity publication-title: Pediatrics. – volume: 8 start-page: 31 year: 2016 end-page: 6 article-title: Retinopathy of prematurity blindness worldwide: phenotypes in the third epidemic publication-title: Eye and Brain. – volume: 257 start-page: 23 issue: 1 year: 2019 end-page: 30 article-title: Foveal microvascular anomalies on optical coherence tomography angiography and the correlation with foveal thickness and visual acuity in retinopathy of prematurity publication-title: Graefes Arch Clin Exp Ophthalmol. – volume: 109 start-page: 1345 issue: 4 year: 2007 end-page: 52 article-title: Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation publication-title: Blood – volume: 5 issue: 19 year: 2020 article-title: IGF1, serum glucose, and retinopathy of prematurity in extremely preterm infants publication-title: JCI Insight. – year: 2022 article-title: Intravitreal bevacizumab injection for retinopathy of prematurity and pulmonary hypertension publication-title: Journal of Perinatology. – volume: 63 start-page: 618 issue: 5 year: 2018 end-page: 37 article-title: Retinopathy of prematurity: a review of risk factors and their clinical significance publication-title: Surv Ophthalmol. – volume: 58 start-page: 261 issue: 4 year: 2021 end-page: 9 article-title: Addressing the Third Epidemic of Retinopathy of Prematurity Through Telemedicine and Technology: A Systematic Review publication-title: J Pediatr Ophthalmol Strabismus. – volume: 26 start-page: 109 issue: 3 year: 2022 end-page: 12 article-title: Retinopathy of prematurity classification updates: possible implications for treatment publication-title: Journal of American Association for Pediatric Ophthalmology and Strabismus. – volume: 5 start-page: 698 issue: 10 year: 2021 end-page: 707 article-title: 2‐year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow‐up of an open label, randomised controlled trial publication-title: Lancet Child Adolesc Health. – volume: 92 start-page: 10457 issue: 23 year: 1995 end-page: 61 article-title: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF‐receptor chimeric proteins publication-title: Proc Natl Acad Sci U S A. – volume: 104 start-page: 541 issue: 4 year: 2020 end-page: 6 article-title: Visual function is reduced in young adults formerly born prematurely: a population‐based study publication-title: British Journal of Ophthalmology. – year: 2018 article-title: Correction to: Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy publication-title: Angiogenesis – volume: 100 start-page: 1523 year: 2011 end-page: 7 article-title: On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment ‐ a review publication-title: Acta paediatrica. – volume: 144 issue: 2 year: 2019 article-title: Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment publication-title: Pediatrics. – volume: 58 start-page: 6419 year: 2017 end-page: 28 article-title: Systemic Inflammation‐Associated Proteins and Retinopathy of Prematurity in Infants Born Before the 28th Week of Gestation publication-title: Invest Ophthalmol Vis Sci. – volume: 328 start-page: 348 issue: 4 year: 2022 end-page: 59 article-title: Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity publication-title: Jama. – volume: 4 start-page: 1565 issue: 11 year: 2009 end-page: 73 article-title: Quantification of oxygen‐induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis publication-title: Nat Protoc. – volume: 382 start-page: 1445 issue: 9902 year: 2013 end-page: 57 article-title: Retinopathy of prematurity publication-title: Lancet. – volume: 172 start-page: 278 issue: 3 year: 2018 end-page: 86 article-title: Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial publication-title: JAMA Pediatr. – volume: 14 start-page: 165 issue: 1 year: 2017 article-title: Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies publication-title: J Neuroinflammation. – volume: 10 start-page: 133 issue: 2 year: 2007 end-page: 40 article-title: Retinopathy of prematurity publication-title: Angiogenesis. – volume: 132 start-page: 1327 issue: 11 year: 2014 end-page: 33 article-title: Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial publication-title: JAMA ophthalmology. – volume: 30 start-page: 45 issue: 99 year: 2017 end-page: 8 article-title: Retinopathy of prematurity: it is time to take action publication-title: Community Eye Health. – volume: 100 start-page: e91 issue: 1 year: 2022 end-page: e9 article-title: Ranibizumab in retinopathy of prematurity ‐ one‐year follow‐up of ophthalmic outcomes and two‐year follow‐up of neurodevelopmental outcomes from the CARE‐ROP study publication-title: Acta Ophthalmol. – volume: 15 start-page: 553 issue: 3 year: 2022 end-page: 7 article-title: National trends in the incidence and management of retinopathy of prematurity in the United States, 2009‐2018 publication-title: J Neonatal Perinatal Med. – volume: 68 start-page: S108 issue: 13 year: 2020 end-page: S14 article-title: Operational guidelines for ROP in India: A summary publication-title: Indian Journal of Ophthalmology. – volume: 190 start-page: 630 issue: 3 year: 2020 end-page: 41 article-title: Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury publication-title: Am J Pathol. – volume: 9 start-page: 19711 issue: 1 year: 2019 article-title: Non‐contact smartphone‐based fundus imaging compared to conventional fundus imaging: a low‐cost alternative for retinopathy of prematurity screening and documentation publication-title: Scientific Reports. – volume: 54 start-page: 8125 issue: 13 year: 2013 end-page: 39 article-title: Systemic inflammation perturbs developmental retinal angiogenesis and neuroretinal function publication-title: Invest Ophthalmol Vis Sci. – start-page: bjophthalmol‐2021‐319254 year: 2021 article-title: Associations between systemic health and retinal nerve fibre layer thickness in preterm infants at 36 weeks postmenstrual age publication-title: British Journal of Ophthalmology. – volume: 9 issue: 5 year: 2019 article-title: Association between sepsis and retinopathy of prematurity: a systematic review and meta‐analysis publication-title: BMJ Open. – volume: 39 start-page: 964 issue: 7 year: 2019 end-page: 73 article-title: Prenatal and postnatal inflammation‐related risk factors for retinopathy of prematurity publication-title: J Perinatol. – volume: 128 start-page: 877 issue: 6 year: 2021 end-page: 88 article-title: Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity publication-title: Ophthalmology. – volume: 122 start-page: 200 issue: 1 year: 2015 end-page: 10 article-title: Pathophysiology and mechanisms of severe retinopathy of prematurity publication-title: Ophthalmology. – volume: 11 start-page: 87 year: 2014 article-title: Neonatal systemic inflammation in rats alters retinal vessel development and simulates pathologic features of retinopathy of prematurity publication-title: J Neuroinflammation. – volume: 35 start-page: 2451 issue: 9 year: 2021 end-page: 3 article-title: The UK practice of Anti‐VEGF therapy for treatment of retinopathy of prematurity publication-title: Eye (Lond). – volume: 91 start-page: 1043 issue: 5 year: 2021 end-page: 8 article-title: Visuopathy of prematurity: is retinopathy just the tip of the iceberg? publication-title: Pediatr Res. – volume: 147 issue: 6 year: 2021 article-title: Trends in Retinopathy of Prematurity Screening and Treatment: 2008‐2018 publication-title: Pediatrics. – volume: 147 issue: 3 year: 2021 article-title: Applications of Artificial Intelligence for Retinopathy of Prematurity Screening publication-title: Pediatrics. – volume: 74 start-page: 35 issue: Suppl 1 year: 2013 end-page: 49 article-title: Preterm‐associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010 publication-title: Pediatr Res. – volume: 125 start-page: 1961 issue: 12 year: 2018 end-page: 6 article-title: A Dosing Study of Bevacizumab for Retinopathy of Prematurity publication-title: Ophthalmology. – volume: 394 start-page: 1551 issue: 10208 year: 2019 end-page: 9 article-title: Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open‐label randomised controlled trial publication-title: Lancet. – volume: 9 start-page: 5 issue: 2 year: 2020 article-title: Artificial Intelligence in Retinopathy of Prematurity Diagnosis publication-title: Translational Vision Science & Technology. – ident: e_1_2_10_14_1 doi: 10.1038/eye.2008.128 – ident: e_1_2_10_44_1 doi: 10.1111/j.1651-2227.2011.02445.x – ident: e_1_2_10_49_1 doi: 10.1001/jamapediatrics.2017.4838 – ident: e_1_2_10_47_1 doi: 10.1001/jama.2022.10564 – ident: e_1_2_10_29_1 doi: 10.1038/s41372-019-0357-2 – ident: e_1_2_10_7_1 doi: 10.1016/S0002-9394(42)92088-9 – ident: e_1_2_10_9_1 doi: 10.1136/fetalneonatal-2011-301121 – ident: e_1_2_10_30_1 doi: 10.1167/iovs.17-21931 – ident: e_1_2_10_39_1 doi: 10.1007/s10456‐018‐9618‐5 – ident: e_1_2_10_5_1 doi: 10.2147/EB.S94436 – ident: e_1_2_10_6_1 doi: 10.1016/S0140-6736(13)60178-6 – ident: e_1_2_10_17_1 doi: 10.1167/tvst.9.2.5 – ident: e_1_2_10_27_1 doi: 10.1001/archophthalmol.2011.319 – ident: e_1_2_10_42_1 doi: 10.1038/s41433-021-01543-9 – ident: e_1_2_10_23_1 doi: 10.1111/apa.15945 – ident: e_1_2_10_65_1 doi: 10.1001/jamaophthalmol.2014.2772 – ident: e_1_2_10_54_1 doi: 10.1136/bjophthalmol‐2021‐319254 – ident: e_1_2_10_48_1 doi: 10.1016/j.ophtha.2018.05.001 – ident: e_1_2_10_53_1 doi: 10.1007/s00417-018-4162-y – ident: e_1_2_10_10_1 doi: 10.1542/peds.2020-039966 – ident: e_1_2_10_34_1 doi: 10.1007/s10456-007-9066-0 – ident: e_1_2_10_63_1 doi: 10.1371/journal.pone.0230678 – ident: e_1_2_10_55_1 doi: 10.1001/jamaophthalmol.2017.2069 – ident: e_1_2_10_19_1 doi: 10.3928/01913913-20210223-01 – ident: e_1_2_10_13_1 doi: 10.1016/j.jaapos.2022.03.003 – ident: e_1_2_10_24_1 doi: 10.1136/bmjopen-2018-025440 – ident: e_1_2_10_22_1 doi: 10.1016/j.survophthal.2018.04.002 – ident: e_1_2_10_26_1 doi: 10.1038/s41598-022-15804-4 – ident: e_1_2_10_60_1 doi: 10.1016/j.ophtha.2020.11.012 – ident: e_1_2_10_52_1 doi: 10.1016/S2352-4642(21)00195-4 – ident: e_1_2_10_32_1 doi: 10.1186/1742-2094-11-87 – ident: e_1_2_10_46_1 doi: 10.1016/S0140-6736(19)31344-3 – ident: e_1_2_10_33_1 doi: 10.1172/jci.insight.140363 – ident: e_1_2_10_51_1 doi: 10.1111/aos.14852 – ident: e_1_2_10_56_1 doi: 10.1136/bjophthalmol-2017-311345 – ident: e_1_2_10_64_1 doi: 10.1038/s41372‐022‐01489‐0 – ident: e_1_2_10_50_1 doi: 10.1016/j.ophtha.2022.06.042 – ident: e_1_2_10_40_1 doi: 10.1182/blood-2006-07-037952 – ident: e_1_2_10_3_1 doi: 10.1001/jamapediatrics.2016.4396 – ident: e_1_2_10_21_1 doi: 10.3389/fped.2021.796143 – ident: e_1_2_10_59_1 doi: 10.1053/j.semperi.2019.05.012 – ident: e_1_2_10_38_1 doi: 10.1073/pnas.92.23.10457 – ident: e_1_2_10_57_1 doi: 10.1136/bjophthalmol-2019-314429 – ident: e_1_2_10_25_1 doi: 10.1097/MD.0000000000017512 – ident: e_1_2_10_61_1 doi: 10.1542/peds.2015-3218 – ident: e_1_2_10_16_1 doi: 10.4103/ijo.IJO_1827_19 – ident: e_1_2_10_31_1 doi: 10.1038/s41598-018-30087-4 – ident: e_1_2_10_45_1 doi: 10.1016/j.ophtha.2016.12.025 – ident: e_1_2_10_2_1 doi: 10.3233/NPM-210826 – ident: e_1_2_10_35_1 doi: 10.1016/j.ophtha.2014.07.050 – ident: e_1_2_10_36_1 doi: 10.1038/nprot.2009.187 – ident: e_1_2_10_28_1 doi: 10.1186/s12974-017-0943-1 – ident: e_1_2_10_58_1 doi: 10.1038/s41390-021-01625-0 – ident: e_1_2_10_8_1 doi: 10.1167/iovs.18-25525 – ident: e_1_2_10_15_1 doi: 10.1542/peds.2018-3061 – ident: e_1_2_10_37_1 doi: 10.1167/iovs.13-12496 – volume: 30 start-page: 45 issue: 99 year: 2017 ident: e_1_2_10_66_1 article-title: Retinopathy of prematurity: it is time to take action publication-title: Community Eye Health. – ident: e_1_2_10_12_1 doi: 10.1016/j.ophtha.2021.05.031 – ident: e_1_2_10_43_1 doi: 10.1056/NEJMoa1007374 – ident: e_1_2_10_18_1 doi: 10.1542/peds.2020-016618 – ident: e_1_2_10_41_1 doi: 10.1016/j.ajpath.2019.11.009 – ident: e_1_2_10_4_1 doi: 10.1038/pr.2013.205 – ident: e_1_2_10_11_1 doi: 10.1038/s41598-019-56155-x – ident: e_1_2_10_62_1 doi: 10.1542/peds.2018-3537 – ident: e_1_2_10_20_1 doi: 10.1016/j.clp.2019.05.008
SSID	ssj0003654
Score	2.6142485
SecondaryResourceType	review_article
Snippet	Retinopathy of prematurity (ROP) is a devastating neurovascular disease of the retina in newborn infants that can lead to vision deficits or even blindness. In...
SourceID	proquest pubmed crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	625
SubjectTerms	Endothelial Growth Factors Humans Infant Infant, Newborn Infant, Premature Retina Retinopathy of Prematurity - diagnosis Retinopathy of Prematurity - etiology Retinopathy of Prematurity - therapy Vascular Endothelial Growth Factor A
Title	Retinopathy of prematurity
URI	https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fdmcn.15468 https://www.ncbi.nlm.nih.gov/pubmed/36408783 https://www.proquest.com/docview/2738493811
Volume	65
WOSCitedRecordID	wos000888468200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1469-8749 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003654 issn: 0012-1622 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1469-8749 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003654 issn: 0012-1622 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFD7MKeKL98umjom-KBTWJs0FfJHNoeDGGA73VpLTDATtxi6C_96k7aZDEcSX0kLaXHpO8p1cvg_gQjOq0MTKw0EYetRI9ISw_qiYsb2hpFypQSo2wdtt0e_LTgGu52dhMn6IxYSb84y0v3YOrvTki5PHr5i4eREmVmDV94lwwg0B7Sz6YcLCjIPZDzyfBUFOTur28Xy-uzwcfcOYy5A1HXOaW_8r7TZs5lizepMZxw4UTLIL6618NX0Pyl133nnoRInfq8NBdTR2BK6pnN0-9Jq3j_U7L9dK8NBCAOEhMm4jO2oHpQC5GeiQKAzRMMKENjVCZKgRUWpNldRcosVxvjJO1DYUyGrkAIrJMDFHUOXcwhA_ZiT2DVXUKM2C2EZxoVbGSO6X4HLeZBHmROJOz-IlmgcUrrJRWtkSnC_SjjL6jB9Tnc1bPrLW7ZYsVGKGs0nkDg5RaVGFzfUw-yWL7xBGa4ILUoKrtOV_ySBqtOrt9K78l8THsOHU5bP9jSdQnI5n5hTW8G36PBlXUmuzV94XFVhtdJu9B_v0dN_-ACpu2Ps
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED90ivri98fm10RfFAprk-bjUdSx4VZEFH0ryTUDQVuZm-B_b9J2VVEE8a0P16a53F1-SS73AzjSjCo0ifJwEIYeNRI9Iaw_KmZsNJSUKzXIySZ4FIn7e3lV5ua4uzBFfYhqw815Rh6vnYO7DelPXp48Yeo2RpiYhhlqkYZjbrjrRlUgJiwsijD7geezICirk7pEno93v85H30DmV8yaTzrtpX_-7jIslmizeVqYxwpMmXQV5vrlefoaNK7djefM0RK_NbNB83noSrjmhHbrcNu-uDnreCVbgocWBAgPkXG7tqN2WgqQm4EOicIQDSNMaNMiRIYaEaXWVEnNJVok5yvjaG1DgaxFNqCWZqnZgibnFoj4CSOJb6iiRmkWJHYdF2pljOR-HY4nOouxLCXuGC0e48mSwnU2zjtbh8NK9rkooPGj1MFE9bG1b3dooVKTjV9id3WISosrbKubxZhU3yGMtgQXpA4nuep_aSA-759F-VPjL8L7MN-56ffiXje63IYFxzVfZDvuQG00HJtdmMXX0cPLcC83vXeuJtm8
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED90ivji98fm10RfFAprk-bjUZxFcSsiCr6V5JqCoO3YVPC_N2m76VAE8a0P16a53F1-SS73AzjWjCo0qfIwC0OPGomeENYfFTM2GkrKlcpKsgkex-LhQd7UuTnuLkxVH2Ky4eY8o4zXzsHNIM2-eHn6jLnbGGFiFuaoY5FpwFz3NrrvTUIxYWFVhtkPPJ8FQV2f1KXyfL49PSN9g5nTqLWcdqLlf_7wCizVeLN9VhnIKsyYfA0W-vWJ-jq0bt2d58IRE7-3i6w9GLoiriWl3QbcRxd355dezZfgoYUBwkNk3K7uqJ2YAuQm0yFRGKJhhAltOoTIUCOi1JoqqblEi-V8ZRyxbSiQdcgmNPIiN9vQ5txCET9lJPUNVdQozYLUruRCrYyR3G_CyVhnCdbFxB2nxVMyXlS4ziZlZ5twNJEdVCU0fpQ6HKs-sRbuji1UborXUeIuD1FpkYVtdasak8l3CKMdwQVpwmmp-l8aSLr987h8av1F-AAWbrpR0ruKr3dg0ZHNV-mOu9B4Gb6aPZjHt5fH0XC_tr0P8zvaZQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Retinopathy+of+prematurity&rft.jtitle=Developmental+medicine+and+child+neurology&rft.au=Dammann%2C+Olaf&rft.au=Hartnett%2C+M.+Elizabeth&rft.au=Stahl%2C+Andreas&rft.date=2023-05-01&rft.issn=0012-1622&rft.eissn=1469-8749&rft.volume=65&rft.issue=5&rft.spage=625&rft.epage=631&rft_id=info:doi/10.1111%2Fdmcn.15468&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_dmcn_15468
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1622&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1622&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1622&client=summon